Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

DIVALPROEX SODIUM

All strengths: General benefit; same patient cost rules

Shared coverage and patient cost rules
StatusGeneral benefit
Patient paysPatient pays: program not supplied; amount cannot be determined.

Other products in the same Health Canada class (N03A, N03AG) — coverage varies; not interchangeable

  • Valproate (Depakene): general benefit
  • Valproic acid (Depakene): general benefit, Not a benefit
  • Vigabatrin (Vigabatrin for Oral Solution, USP 500mg): limited Use 136, Listing status unconfirmed
  • Carbamazepine (Tegretol): general benefit, Limited Use, Not a benefit, Listing status unconfirmed
  • Clonazepam (Rivotril): general benefit
  • Ethosuximide (Zarontin): general benefit

14 more in the class list below

Apo-Divalproex · DIN 02239698 · 125mg · enteric-coated tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Apo-Divalproex · DIN 02239698 Manufacturer: Apotex Inc.; listing date 1999-09-15 Health Canada: Marketed since 2021-12-21 · brand APO-DIVALPROEX · ATC N03AG01 VALPROIC ACID · form Tablet (delayed-release) · route Oral · ingredients VALPROIC ACID (DIVALPROEX SODIUM) 125 MG · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Apo-Divalproex: Formulary list price $0.1539/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1539 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=63179 · Verify on the e-Formulary ↗ (DIN 02239698)

Source record
DIN 02239698: Apo-Divalproex Raw flags: sec3=Y Item: 281200047; group id 427; item number 1061; lccId None; manufacturer id APX Source form: Ent Tab; strength: 125mg Recorded listing: General benefit Source prices (unrounded): $0.1539; ministry $0.1539 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02239698 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=63179
Interchangeable products
Epival · DIN 00596418 · $0.1539 Mylan-Divalproex · DIN 02458926 · $0.1539
Shortage status: resolved shortage (ended 2023-08-31); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02239698
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Epival · DIN 00596418 · 125mg · enteric-coated tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Savings card: RxHelp ONE lists Epival (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim. (rxhelp.ca ↗)
1 brand, same coverage
Epival · DIN 00596418 Manufacturer: BGP Pharma ULC; listing date 1996-10-01 Health Canada: Marketed since 2016-11-29 · brand EPIVAL · ATC N03AG01 VALPROIC ACID · form Tablet (delayed-release) · route Oral · ingredients VALPROIC ACID (DIVALPROEX SODIUM) 125 MG · company Bgp pharma ulc · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $0.1539 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=5676 · Verify on the e-Formulary ↗ (DIN 00596418)

Source record
DIN 00596418: Epival Raw flags: sec3=Y Item: 281200047; group id 427; item number 1061; lccId None; manufacturer id BGP Source form: Ent Tab; strength: 125mg Recorded listing: General benefit Source prices (unrounded): $0.3828; ministry $0.1539 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00596418 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=5676
Interchangeable products
Apo-Divalproex · DIN 02239698 · $0.1539 Mylan-Divalproex · DIN 02458926 · $0.1539
Shortage status: avoided shortage; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00596418
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Mylan-Divalproex · DIN 02458926 · 125mg · enteric-coated tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Mylan-Divalproex · DIN 02458926 Manufacturer: Mylan Pharmaceuticals ULC; listing date 2017-06-29 Health Canada: Marketed since 2017-04-21 · brand MYLAN-DIVALPROEX · ATC N03AG01 VALPROIC ACID · form Tablet (delayed-release) · route Oral · ingredients VALPROIC ACID (DIVALPROEX SODIUM) 125 MG · company Mylan pharmaceuticals ulc · schedule Prescription
Check this DIN again · Health Canada product record

Mylan-Divalproex: Formulary list price $0.1539/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1539 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94597 · Verify on the e-Formulary ↗ (DIN 02458926)

Source record
DIN 02458926: Mylan-Divalproex Raw flags: sec3=Y Item: 281200047; group id 427; item number 1061; lccId None; manufacturer id MYL Source form: Ent Tab; strength: 125mg Recorded listing: General benefit Source prices (unrounded): $0.1539; ministry $0.1539 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02458926 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94597
Interchangeable products
Apo-Divalproex · DIN 02239698 · $0.1539 Epival · DIN 00596418 · $0.1539
Shortage status: resolved shortage (ended 2023-02-10); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02458926
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Apo-Divalproex · DIN 02239699 · 250mg · enteric-coated tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Apo-Divalproex · DIN 02239699 Manufacturer: Apotex Inc.; listing date 1999-09-15 Health Canada: Marketed since 2021-12-21 · brand APO-DIVALPROEX · ATC N03AG01 VALPROIC ACID · form Tablet (delayed-release) · route Oral · ingredients VALPROIC ACID (DIVALPROEX SODIUM) 250 MG · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Apo-Divalproex: Formulary list price $0.2767/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2767 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=63180 · Verify on the e-Formulary ↗ (DIN 02239699)

Source record
DIN 02239699: Apo-Divalproex Raw flags: sec3=Y Item: 281200046; group id 427; item number 1062; lccId None; manufacturer id APX Source form: Ent Tab; strength: 250mg Recorded listing: General benefit Source prices (unrounded): $0.2767; ministry $0.2767 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02239699 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=63180
Interchangeable products
Epival · DIN 00596426 · $0.2767 Mylan-Divalproex · DIN 02458934 · $0.2767
Shortage status: active shortage (reported 2026-07-14, estimated to end 2026-10-09, last updated 2026-09-04); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02239699
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Epival · DIN 00596426 · 250mg · enteric-coated tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Savings card: RxHelp ONE lists Epival (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim. (rxhelp.ca ↗)
1 brand, same coverage
Epival · DIN 00596426 Manufacturer: BGP Pharma ULC; listing date 1996-10-01 Health Canada: Marketed since 2016-07-22 · brand EPIVAL · ATC N03AG01 VALPROIC ACID · form Tablet (delayed-release) · route Oral · ingredients VALPROIC ACID (DIVALPROEX SODIUM) 250 MG · company Bgp pharma ulc · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $0.2767 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=5677 · Verify on the e-Formulary ↗ (DIN 00596426)

Source record
DIN 00596426: Epival Raw flags: sec3=Y Item: 281200046; group id 427; item number 1062; lccId None; manufacturer id BGP Source form: Ent Tab; strength: 250mg Recorded listing: General benefit Source prices (unrounded): $0.6883; ministry $0.2767 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00596426 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=5677
Interchangeable products
Apo-Divalproex · DIN 02239699 · $0.2767 Mylan-Divalproex · DIN 02458934 · $0.2767
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00596426
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Mylan-Divalproex · DIN 02458934 · 250mg · enteric-coated tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Mylan-Divalproex · DIN 02458934 Manufacturer: Mylan Pharmaceuticals ULC; listing date 2017-06-29 Health Canada: Marketed since 2017-05-21 · brand MYLAN-DIVALPROEX · ATC N03AG01 VALPROIC ACID · form Tablet (delayed-release) · route Oral · ingredients VALPROIC ACID (DIVALPROEX SODIUM) 250 MG · company Mylan pharmaceuticals ulc · schedule Prescription
Check this DIN again · Health Canada product record

Mylan-Divalproex: Formulary list price $0.2767/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2767 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94598 · Verify on the e-Formulary ↗ (DIN 02458934)

Source record
DIN 02458934: Mylan-Divalproex Raw flags: sec3=Y Item: 281200046; group id 427; item number 1062; lccId None; manufacturer id MYL Source form: Ent Tab; strength: 250mg Recorded listing: General benefit Source prices (unrounded): $0.2767; ministry $0.2767 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02458934 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94598
Interchangeable products
Apo-Divalproex · DIN 02239699 · $0.2767 Epival · DIN 00596426 · $0.2767
Shortage status: resolved shortage (ended 2023-01-16); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02458934
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Apo-Divalproex · DIN 02239700 · 500mg · enteric-coated tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Apo-Divalproex · DIN 02239700 Manufacturer: Apotex Inc.; listing date 1999-09-15 Health Canada: Marketed since 2021-12-21 · brand APO-DIVALPROEX · ATC N03AG01 VALPROIC ACID · form Tablet (delayed-release) · route Oral · ingredients VALPROIC ACID (DIVALPROEX SODIUM) 500 MG · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Apo-Divalproex: Formulary list price $0.5537/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.5537 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=63181 · Verify on the e-Formulary ↗ (DIN 02239700)

Source record
DIN 02239700: Apo-Divalproex Raw flags: sec3=Y Item: 281200045; group id 427; item number 1063; lccId None; manufacturer id APX Source form: Ent Tab; strength: 500mg Recorded listing: General benefit Source prices (unrounded): $0.5537; ministry $0.5537 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02239700 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=63181
Interchangeable products
Epival · DIN 00596434 · $0.5537 Mylan-Divalproex · DIN 02459019 · $0.5537
Shortage status: resolved shortage (ended 2024-08-15); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02239700
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Epival · DIN 00596434 · 500mg · enteric-coated tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Savings card: RxHelp ONE lists Epival (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim. (rxhelp.ca ↗)
1 brand, same coverage
Epival · DIN 00596434 Manufacturer: BGP Pharma ULC; listing date 1996-10-01 Health Canada: Marketed since 2016-05-25 · brand EPIVAL · ATC N03AG01 VALPROIC ACID · form Tablet (delayed-release) · route Oral · ingredients VALPROIC ACID (DIVALPROEX SODIUM) 500 MG · company Bgp pharma ulc · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $0.5537 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=5678 · Verify on the e-Formulary ↗ (DIN 00596434)

Source record
DIN 00596434: Epival Raw flags: sec3=Y Item: 281200045; group id 427; item number 1063; lccId None; manufacturer id BGP Source form: Ent Tab; strength: 500mg Recorded listing: General benefit Source prices (unrounded): $1.3773; ministry $0.5537 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00596434 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=5678
Interchangeable products
Apo-Divalproex · DIN 02239700 · $0.5537 Mylan-Divalproex · DIN 02459019 · $0.5537
Shortage status: avoided shortage; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00596434
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Mylan-Divalproex · DIN 02459019 · 500mg · enteric-coated tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Mylan-Divalproex · DIN 02459019 Manufacturer: Mylan Pharmaceuticals ULC; listing date 2017-06-29 Health Canada: Marketed since 2017-04-11 · brand MYLAN-DIVALPROEX · ATC N03AG01 VALPROIC ACID · form Tablet (delayed-release) · route Oral · ingredients VALPROIC ACID (DIVALPROEX SODIUM) 500 MG · company Mylan pharmaceuticals ulc · schedule Prescription
Check this DIN again · Health Canada product record

Mylan-Divalproex: Formulary list price $0.5537/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.5537 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94599 · Verify on the e-Formulary ↗ (DIN 02459019)

Source record
DIN 02459019: Mylan-Divalproex Raw flags: sec3=Y Item: 281200045; group id 427; item number 1063; lccId None; manufacturer id MYL Source form: Ent Tab; strength: 500mg Recorded listing: General benefit Source prices (unrounded): $0.5537; ministry $0.5537 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02459019 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94599
Interchangeable products
Apo-Divalproex · DIN 02239700 · $0.5537 Epival · DIN 00596434 · $0.5537
Shortage status: avoided shortage; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02459019
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (28:12 Anticonvulsants) and how they are covered

Matched class: 28:12 Anticonvulsants

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: CLONAZEPAM, ETHOSUXIMIDE, LAMOTRIGINE, VALPROATE SODIUM Some products covered without a code (check the product listing): CARBAMAZEPINE, GABAPENTIN, PHENYTOIN (DIPHENYLHYDANTOIN), PHENYTOIN (DIPHENYLHYDANTOIN) SODIUM, PREGABALIN, PRIMIDONE, TOPIRAMATE, VALPROIC ACID 28:12 Anticonvulsants

VALPROATE SODIUM

· 5 products · General benefit · strengths: 50mg/mL · O/L

VALPROIC ACID

· 5 products · Listed, not a benefit (2), General benefit (3) · strengths: 250mg, 500mg · Cap, Ent Cap

VIGABATRIN

· 3 products · Temporary benefit (2), Limited Use, codes 136 (1) · strengths: 500mg/Sachet, 500mg · Pd for Oral Sol, Tab

CARBAMAZEPINE

· 15 products · Listed, not a benefit (3), General benefit (6), Temporary benefit (2), Limited Use, codes 67 (4) · strengths: 100mg, 200mg, 400mg, 100mg/5mL · Chew Tab, ER Tab, LA Tab, Oral Susp, Tab

CLONAZEPAM

· 9 products · General benefit · strengths: 0.5mg, 2mg · Tab

ETHOSUXIMIDE

· 4 products · General benefit · strengths: 250mg, 50mg/mL · Cap, O/L

LAMOTRIGINE

· 28 products · General benefit · strengths: 25mg, 100mg, 150mg · Tab

PHENYTOIN (DIPHENYLHYDANTOIN)

· 4 products · General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (2), General benefit (2) · strengths: 6mg/mL, 25mg/mL, 50mg · O/L, Tab

PHENYTOIN (DIPHENYLHYDANTOIN) SODIUM

· 4 products · General benefit (3), Limited Use, codes 481, 657 (1) · strengths: 30mg, 100mg, 50mg/mL · Cap, Inj Sol (Preservative Free)

PRIMIDONE

· 4 products · General benefit (2), Listed, not a benefit (2) · strengths: 125mg, 250mg · Tab

TOPIRAMATE

· 54 products · Limited Use, codes 321 (2), Off-Formulary Interchangeable, not an ODB benefit (3), General benefit (49) · strengths: 15mg, 25mg, 50mg, 100mg, 200mg · Sprinkle Cap, Tab

BRIVARACETAM

· 12 products · Limited Use, codes 548 · strengths: 10mg, 25mg, 50mg, 75mg, 100mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 28:12 and 11 more
Full class listing Related classes: 28:08 Analgesics, 28:10 Opiate Antagonists, 28:16 Psychotherapeutic Agents, 28:20 C.N.S. Stimulants, 28:24 Sedatives and Hypnotics, 28:36 Antiparkinsonian Agents, 28:92 Miscellaneous Central Nervous System Drugs Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: simple or complex absence seizures
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. Covered without a code on the Ontario formulary: VALPROATE SODIUM VALPROATE SODIUM · General benefit Indications DEPAKENE (valproic acid oral solution) is indicated for: • use as sole or adjunctive therapy in the treatment of simple or complex absence seizures, including petit mal, and is useful in primary generalized seizures with tonic-clonic manifestations. PM: https://pdf.hres.ca/dpd_pm/00084557.PDF; date 2026-04-30; DIN 00443832; fetched 2026-09-10 Product monograph VALPROIC ACID · Listed, not a benefit (2), General benefit (3) (valproic acid) are indicated for: • use as sole or adjunctive therapy in the treatment of simple or complex absence seizures, including petit mal, and is useful in primary generalized seizures with tonic-clonic manifestations. PM: https://pdf.hres.ca/dpd_pm/00083584.PDF; date 2026-02-23; DIN 02230768; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
1. Indications EPIVAL® (divalproex sodium delayed-release tablets) is indicated for: Epilepsy • use as sole or adjunctive therapy in the treatment of simple or complex absence seizures, including petit mal, and is useful in primary generalized seizures with tonic-clonic manifestations. • use adjunctively in patients with multiple seizure types which include either absence or tonic-clonic seizures. In accordance with the International Classification of Seizures, simple absence is defined as a very brief clouding of the sensorium or loss of consciousness (lasting usually 2 to 15 seconds), accompanied by certain generalized epileptic discharges without other detectable clinical signs. Complex absence is the term used when other signs are also present. Acute Mania • the treatment of the manic episodes associated with bipolar disorder (DSM-III-R). The safety and efficacy of EPIVAL for long-term use in mania, that is for more than 3 weeks, have not been evaluated in controlled trials. See 2 Contraindications, and 7 Hepatic/Biliary/Pancreatic, Serious or Fatal Hepatotoxicity for statement regarding serious or fatal hepatic dysfunction. 1.1. Pediatrics Pediatrics (< 18 years… https://pdf.hres.ca/dpd_pm/00084579.PDF PM date: 2026-04-30 Source product: EPIVAL; DIN 00596418; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Apo-Divalproex · DIN 02239699 Shortage status: active shortage (reported 2026-07-14, estimated to end 2026-10-09, last updated 2026-09-04); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02239699

Check this DIN again